I-Mab Biopharma
IMAB
#9017
Rank
NZ$0.12 B
Marketcap
$1.59
Share price
-2.99%
Change (1 day)
-36.57%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): NZ$50.43 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is NZ$62.24 Million. In 2022 the company made a revenue of -NZ$54.99 Million a decrease over the revenue in the year 2021 that were of NZ$23.64 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$50.43 M
2022-NZ$54.99 Million-332.55%
2021NZ$23.64 M-94.16%
2020 NZ$0.40 B5407.66%
2019 NZ$7.35 M-45.08%
2018 NZ$13.38 M340.25%
2017NZ$3.04 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
NZ$0.38 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$1.22 B 1,870.10%๐Ÿ‡บ๐Ÿ‡ธ USA